Business Context and Reporting Period
This Form 8-K is a current report filed by Helix Acquisition Corp. II (not Bridgebio Oncology Therapeutics, Inc.) on February 8, 2025. The filing discloses the appointment of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance.
Material Changes
- Board Appointment: Mr. Albert A. Holman, III was appointed as a Class III director, with a term expiring at the Company's third annual meeting of shareholders.
- Committee Assignment: Mr. Holman was appointed to serve on the Audit Committee.
- Share Transfer: The Company's Sponsor, Helix Holdings II LLC, transferred 30,000 Class B ordinary shares to Mr. Holman in connection with his appointment.
Guidance, Outlook, and Management Commentary
Management commentary highlights Mr. Holman's extensive background in life sciences investment banking, including his role as Founder and Co-Managing Partner of Chestnut Partners, Inc. The Board determined that his expertise in debt and equity capital formation and mergers and acquisitions adds significant value to the Board and the Audit Committee. No financial guidance or outlook was provided in this filing.
Important Facts for Investor Verification
- Verify the identity of the registrant as Helix Acquisition Corp. II (HLXB), distinct from Bridgebio Oncology Therapeutics, Inc.
- Confirm the transfer of 30,000 Class B ordinary shares from the Sponsor to the new director.
- Review the attached exhibits (10.1 and 10.2) for the full terms of the Letter Agreement and Joinder Agreement.
- Note that the filing date is February 8, 2025, with the report signed on February 10, 2025.